AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
2min chapter
Special Edition: Time in Range: Medication Management – March 2023
Diabetes Core Update
Is There a Need for Cardio Renal Risk Reduction?
If we can remove the need for cardio renal risk reduction from the table and that's not a factor, the guideline stress really focusing on achieving individualized glysemic and weight management goals. The guidelines also acknowledge that we should be thinking about potentially adding on medications indicated for the treatment of obesity or even considering metabolic surgery when appropriated indicated. Dr. Scholnick: I have to mention our recently approved dual GLP one GIP receptor agonist, herzepitide. We've seen some dramatic weight loss in the few people I've seen on this medication.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode